LENSAR (LNSR) Stock: Buy, Sell, or Hold?
LNSR - LENSAR, Inc. Common Stock
$5.69
-0.12 (-2.07%)
▼
5d:
-6.87%
30d:
-21.52%
90d:
-1.22%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When LNSR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LNSR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: LNSR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: LNSR is currently trading at $5.69, which is considered oversold relative to its 30-day fair value range of $6.10 to $7.21. From a valuation perspective, the stock is trading at a discount (Forward PE: -11.2) compared to its historical average (14.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LNSR is in a uptrend. The price is currently testing key support at $5.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.33 (+99.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LNSR is in a uptrend. The price is currently testing key support at $5.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.33 (+99.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.10 -
$7.21
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.2% below Wall St target ($11.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (55/100) — watch for confirmation
- CAUTION: 5-day price weakness (-6.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$6.10 -
$7.21
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.68
Resistance Level
$6.54
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.16
Wall Street Target
$11.33
(+99.2%)
Revenue Growth (YoY)
18.4%
Profit Margin
57.6%
PE vs Historical
-11.2 vs 14.6
CHEAP
Share & Embed Analysis
Last updated: October 22, 2026 5:32 AM ET
Data refreshes hourly during market hours. Next update: 6:32 AM
Data refreshes hourly during market hours. Next update: 6:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LNSR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 50 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 59 HOLD |
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 53 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
